CS MEDICA strives toward granting patent acceptance on all present and future treatment products. All CS MEDICA's treatment products (topical and oral) as of today are patented in accordance with PCT (Patent Cooperation Treaty), covering 153 nations across the globe. The Company currently has seven proceeding patents that are filed and pending. The 15[th] of September 2022 the USA national patent application on Arthritis & Psoriasis Gel have been published.

All patent applications are continuations of the patent application earlier submitted. The status of the patent applications are shown in below table:

[image]

• Phase I   (PRI):   DK application (PRI)
• Phase II  (PCT):  continuations of the DK application to the PCT application, covering 153 nations across the globe
• Phase III (ORD): continuations of the PCT application to national applications

After the PCT (phase II), the patents will enter national phases (phase III) where CS MEDICA needs to determine in which countries and/or regions the Company intend to pursue patents. It is the current strategy to extend this protection in the US, China, Europe, Australia, New Zealand, Japan, India, Canada, Israel, and South Korea. 

The published patents of continuations of patent application can be found on the webpage patentscope.wipo.int by searching for "CS Medica and Henriksen" or via this link. (https://patentscope.wipo.int/search/en/result.jsf?_vid=P10-L8BDML-06240)

The patents are intended to strengthen the protection of the Company's products. If granted, the patents will protect the technology til 2039 (patent filed in 2019) and 2041 (patents filed in 2021).

With this patent update , CS MEDICA are now finalising the strategic objectives covering patents for the second half of 2021/2022.